THE SHARE: Change: -0.02 SEK (-9.32%) / Price: 0.20 SEK / Sep 25, 2025, 5:29 pm (CEST)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Press Releases

  • 9 Jan, 2020
    Lead compound appointed in the Tumorad® -project
  • 9 Jan, 2020
    Lead compound utsedd i Tumorad® -projektet
  • 19 Nov, 2019
    Valberedning utsedd inför årsstämman 2020 i Spago Nanomedical AB
  • 13 Nov, 2019
    Extrastämma godkänner incitamentsprogram
  • 13 Nov, 2019
    Spago Nanomedical delårsrapport juli – september 2019
  • 16 Oct, 2019
    Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
  • 28 Sep, 2019
    First patient dosed in the SPAGOPIX-01 study
  • 28 Sep, 2019
    Första patienten doserad i SPAGOPIX-01 studien
  • 26 Aug, 2019
    Spago Nanomedical has initiated the clinical trial SPAGOPIX-01
  • 26 Aug, 2019
    Spago initierar den kliniska studien SPAGOPIX-01
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 21
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2025 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications